Publications

Show Filters

Searches all publications.

Search Fulltext

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-02-19
    E.g., 2018-02-19

Articles

49943 items
12:00 AM, Feb 24, 2000  |  BC Extra | Financial News

Dusa private placement

DUSA, a developer of photodynamic therapies, will raise $42.8 million in a private placement of 1.5 million shares to Invesco Funds Group. The purchase price of $28.50 represents a 5 percent discount to the closing...
12:00 AM, Feb 24, 2000  |  BC Extra | Financial News

Celera's good day

Shares of CRA shot up $58 (35 percent) to $225 on Thursday on no news. The company's split-adjusted 52-week range is $7.063-$225....
12:00 AM, Feb 24, 2000  |  BC Extra | Financial News

Esperion files for IPO

Esperion (Ann Arbor, Mich.), which is developing HDL-raising therapeutics to treat cardiovascular and metabolic diseases, filed to raise up to $138 million in an IPO. The deal will be underwritten by Robertson Stephens; Chase H&Q;...
12:00 AM, Feb 24, 2000  |  BC Extra | Financial News

Cor sells shoe

CORR raised $50 million through the sale of the entire overallotment in its February note offering, bringing to $300 million the total raised in the deal....
12:00 AM, Feb 24, 2000  |  BC Extra | Financial News

Organogenesis raises $9.4 million

ORG raised $9.4 million in a private placement of 688,925 shares at $14 with Gruntal acting as agent. The offering increases ORG's shares outstanding to 31.3 million, and a portion of the proceeds will be...
12:00 AM, Feb 24, 2000  |  BC Extra | Financial News

UroGen raises $17 million

UROG, which is developing hemophilia and prostate cancer treatments, completed a private placement of 2 million shares at $8.50 a share to the Aries Funds. Evolution Capital was the placement agent....
12:00 AM, Feb 24, 2000  |  BC Extra | Financial News

Warburg begins coverage of Integra

Warburg Dillon Read analyst Emil Westergaard began coverage with a "buy" and a $22 price target. Westergaard estimates 2000 and 2001 revenues of $59 million and $69 million, respectively. The biomaterials company was up $3.875...
12:00 AM, Feb 23, 2000  |  BC Extra | Top Story

Financing flood continues

Virologic (South San Francisco, Calif.), which is developing its PhenoSense viral drug resistance detection technology, filed to raise up to $75 million in an IPO. The offering will be underwritten by CIBC Worldmarkets; ING Barings;...
12:00 AM, Feb 23, 2000  |  BC Extra | Company News

Lexicon deal with Boehringer Ingelheim

Boehringer Ingelheim received access to Lexicon's OmniBank gene sequence database and library of 60,000 knockout mouse clones for use in determining the function of genes that are potential drug targets. Boehringer Ingelheim also received access...
12:00 AM, Feb 23, 2000  |  BC Extra | Clinical News

Phase II Remune data

Data from a 297-patient Phase II study in Thailand of Immune Response's Remune inactivated gp120-depleted HIV-1 immunogen with incomplete Freund's adjuvant showed a significant increase in CD4 T cells, the trial's primary end point, after...

Pages